Liquid biopsy could help optimize treatment in early breast cancer patients
10 Jun 2016
Liquid biopsy can be used to evaluate tumor evolution and identify chemo-resistant tumor cells (CTC) in HER2 negative early breast cancer patients, according to results from the pilot phase of a trial sponsored by EORTC published in the European Journal of Cancer.
“The detection of chemo-resistant tumor cells in early breast cancer patients has been associated with a worse long-term prognosis,” says Dr Michail Ignatiadis from Institut Jules Bordet, the principal investigator for the TreatCTC trial. “Systematically testing these women using a liquid biopsy approach may therefore allow them to benefit from new therapeutic approaches to improve their long-term treatment outcomes.”
These results are the outcome of the pilot phase of the Treat CTC trial, which currently involves 81 hospitals across Europe, targeting HER2 negative patients that have completed neoadjuvant or adjuvant chemotherapy and surgery. The pilot phase reports on the first 350 screened patients, of which 39 (11%) have liquid biopsies that show the presence of chemoresistant CTCs, which have been associated with shorter disease-free survival and overall survival. “Getting consistent readings of liquid biopsy results proved to be one of the most challenging parts of this pilot,” said Vassilis Golfinopoulos, Medical Director at EORTC. “Rigorous follow-up and regular trainings were centrally coordinated by the EORTC to harmonize results across the network in order to validate this testing methodology.”
The pilot provides important insights into the use of liquid biopsy methods to monitor tumor evolution to evaluate additional treatment options in non-metastatic patients. It establishes recommended methodologies for quality assurance in clinical testing and validation of liquid biopsies and demonstrates the feasibility of real-time screening of early breast cancer patients for CTCs in an international, multi-lab setting.
The study is currently open and recruiting in 5 countries (Belgium, France, Germany, Austria and UK) and eighty-one sites.
Related News
Meet the new EORTC Board
9 Jul 2024
We are pleased to announce the release of the EORTC 2023 Annual Report
17 Jun 2024
Dr Denis Lacombe, EORTC CEO, appointed stakeholder co-chair of ACT EU advisory group
24 May 2024
Clinical Trials Day 2024: a Q&A on pragmatic clinical trials
20 May 2024
EORTC/EMA workshop suggests an international way forward for treatment optimisation studies
8 May 2024
EORTC’s Participation at the ESTRO Congress 2024
29 Apr 2024
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024